Celcuity Inc. (NASDAQ:CELC) Given Average Rating of “Buy” by Brokerages

Celcuity Inc. (NASDAQ:CELC) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $30.17.

Separately, Needham & Company LLC raised their price objective on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CELC. Soleus Capital Management L.P. grew its holdings in Celcuity by 106.0% during the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock worth $33,577,000 after purchasing an additional 1,319,700 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Celcuity by 42.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company’s stock worth $35,062,000 after acquiring an additional 803,575 shares during the period. State Street Corp increased its holdings in shares of Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Celcuity in the 4th quarter valued at $8,468,000. Finally, Candriam S.C.A. acquired a new stake in Celcuity during the 4th quarter valued at $3,450,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Down 2.8 %

Shares of CELC stock opened at $10.24 on Friday. The firm’s fifty day moving average price is $11.20 and its two-hundred day moving average price is $12.96. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity has a 1 year low of $8.53 and a 1 year high of $22.04. The firm has a market capitalization of $380.21 million, a P/E ratio of -3.92 and a beta of 0.65.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.